A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.

ABSTRACT:

Introduction

This investigator-initiated study explores the safety, maximum tolerated dose, clinical response, and pharmacokinetics of hydroxychloroquine (HCQ) with and without erlotinib in patients with advanced non-small-cell lung cancer.

Methods

Patients with prior clinical benefit from an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor were randomized to HCQ or HCQ plus erlotinib in a 3 + 3 dose-escalation schema.

Results

Twenty-seven patients were treated, eight with HCQ (arm A) and 19 with HCQ plus erlotinib (arm B). EGFR mutations were detected in 74% of the patients and 85% had received two or more prior therapies. Arm A had no dose-limiting toxicities, but the maximum tolerated dose was not reached as this arm closed early to increase overal

SUBMITTER: Goldberg SB 

PROVIDER: S-EPMC3791327 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature